Health Economics›B-cell acute lymphoblastic leukemia pediatric›Interim maintenance

Interim maintenance

B-cell acute lymphoblastic leukemia pediatric · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Methotrexate and Vincristine Variant #01	—	R 4 191	14d	—	—	~2	~R 4 720 indirect	—
Mercaptopurine, Methotrexate, Vincristine Variant #02	—	R 2 001	56d	—	—	~2	~R 4 002 indirect	—

2 of 2 regimens shown